- Home
- TCRX vs FORA Comparison
TCRX vs FORA Comparison
Compare TCRX & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- FORA
- Stock Information
- Founded
- TCRX 2018
- FORA 2014
- Country
- TCRX United States
- FORA United States
- Employees
- TCRX N/A
- FORA N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- FORA Computer Software: Prepackaged Software
- Sector
- TCRX Health Care
- FORA Technology
- Exchange
- TCRX Nasdaq
- FORA Nasdaq
- Market Cap
- TCRX 64.1M
- FORA 69.4M
- IPO Year
- TCRX 2021
- FORA N/A
- Fundamental
- Price
- TCRX $0.98
- FORA $2.11
- Analyst Decision
- TCRX Strong Buy
- FORA
- Analyst Count
- TCRX 7
- FORA 0
- Target Price
- TCRX $8.50
- FORA N/A
- AVG Volume (30 Days)
- TCRX 1.1M
- FORA 39.0K
- Earning Date
- TCRX 11-12-2025
- FORA 11-14-2025
- Dividend Yield
- TCRX N/A
- FORA N/A
- EPS Growth
- TCRX N/A
- FORA N/A
- EPS
- TCRX N/A
- FORA N/A
- Revenue
- TCRX $8,423,000.00
- FORA $28,106,911.00
- Revenue This Year
- TCRX $255.18
- FORA $47.82
- Revenue Next Year
- TCRX N/A
- FORA $10.11
- P/E Ratio
- TCRX N/A
- FORA N/A
- Revenue Growth
- TCRX N/A
- FORA 37.47
- 52 Week Low
- TCRX $0.96
- FORA $1.64
- 52 Week High
- TCRX $4.94
- FORA $4.03
- Technical
- Relative Strength Index (RSI)
- TCRX 28.55
- FORA 44.32
- Support Level
- TCRX $0.96
- FORA $2.05
- Resistance Level
- TCRX $1.25
- FORA $2.30
- Average True Range (ATR)
- TCRX 0.13
- FORA 0.10
- MACD
- TCRX -0.02
- FORA -0.01
- Stochastic Oscillator
- TCRX 4.00
- FORA 28.78
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.